Aromatase inhibitors and the risk of colorectal cancer in postmenopausal women with breast cancer.

ABSTRACT:

Background

A large trial of postmenopausal women with breast cancer reported an imbalance in colorectal cancer events with aromatase inhibitors (AIs), compared with tamoxifen in the adjuvant setting. This unexpected signal was observed within 3 years of randomization. To date, no observational studies have examined this important safety question in the natural setting of clinical practice. Thus, the objective of this study was to determine whether AIs, when compared with tamoxifen, are associated with increased risk of colorectal cancer in postmenopausal women with breast cancer.

Patients and methods

Using the UK Clinical Practice Research Datalink, we identified women, at least 55 years of age, with breast cancer newly treated with either AIs or tamoxifen between 1 January

SUBMITTER: Khosrow-Khavar F 

PROVIDER: S-EPMC5889043 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature